Company Performance for Fiscal Year 2021/22
In a video presentation, Carl Zeiss Meditec AG, a leading figure in the medical technology industry, showcased its impressive performance for the fiscal year 2021/22. Dr. Markus Weber, the esteemed President and CEO, alongside the CFO, delivered a comprehensive overview of the company’s financial health and strategic directions. Despite ongoing geopolitical tensions, macroeconomic risks, and a volatile global market, Carl Zeiss Meditec has reported a commendable revenue increase to €1,903 million, up 15.5% from the previous year. This growth is even more significant considering the adjusted currency effects, at 13.3%.
Key Financial Highlights
Orders received saw a notable jump to €2,251 million, reflecting a 30.1% increase (27.7% adjusted for currency effects), underscoring the robust demand for the company’s innovative medical solutions. The earnings before interest and taxes (EBIT) also saw an uptick to €397 million, with an EBIT margin of 20.9%, albeit a slight decrease from the prior year’s 22.7%, indicating a strategic focus on sustainable profitability.
Growth Drivers and Regional Performance
The Ophthalmic Devices and Microsurgery strategic business units have driven growth, with significant revenue increases reported. The company also highlighted sustained growth across all geographical regions, with the APAC region, particularly China and India, making the strongest contributions.
Outlook and Strategic Initiatives for 2022/23
Despite supply chain disruptions and inflationary pressures, Carl Zeiss Meditec remains optimistic about the fiscal year 2022/23, projecting revenue growth at least as high as market growth and an EBIT margin between 19 and 21%. This optimism is backed by a solid order book, strategic investments in R&D and marketing, and a commitment to delivering shareholder value, exemplified by the proposed dividend increase to €1.10 per share.
December 12, 2022
04:02 
